The Latest Breaking News from Novo Nordisk

Hims & Hers Stock Soars on Novo Nordisk Collaboration

Hims & Hers stock rallies by over 25% on news of a collaboration with Novo Nordisk and its weight loss flagship products, and that's not all.

MarketBeat · Apr 30, 2025

Ozempic maker spending more than $3m to lobby fat cats in Washington as weight-loss drugs faces regulatory decisions

Novo Nordisk has hired multiple lobbying firms to persuade lawmakers to take a harder line on companies producing versions of the drugs that have not been approved by the FDA

The Independent UK · Apr 29, 2025

You might soon be able to get Wegovy from an online shop — here is where you need to visit

The move comes as Danish drugmaker Novo Nordisk has acted to slash the popular weight loss drug’s price

The Independent UK · Apr 29, 2025

WeightWatchers Filing For Bankruptcy: Iconic Program Founded In 1963 Loses Clients To Ozempic And More

Founded in 1963, WeightWatchers faces bankruptcy with £1.25 billion ($1.6 billion) in debt, losing clients to drugs like Ozempic. Can the iconic programme survive?

International Business Times UK · Apr 10, 2025

EU drug companies warn of exodus to US as Trump threatens import tariffs

Von der Leyen urged to take ‘rapid and radical action’ as president says tariffs on pharmaceuticals coming ‘shortly’

The Guardian - UK · Apr 9, 2025

Europe’s pharma titans confront von der Leyen as Trump plans ’major’ tariffs

Novo Nordisk and Sanofi were among the companies threatening to hasten their exits to the U.S., as Trump promised pharma tariffs were coming “shortly.”

Fortune · Apr 9, 2025

Europe braces for Trump’s tariffs: What could the economic damage be?

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and forcing the ECB to consider rate cuts.

Euronews · Apr 2, 2025

These 2 Mega-Cap Stocks Could Be Even Cheaper Buys Than Nvidia on the Dip

The market appears to be underestimating just how much these two companies can grow.

Barchart · Apr 1, 2025

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews · Apr 1, 2025

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews · Mar 28, 2025